Advertisement

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

  • Asim AminEmail author
  • Elizabeth R. Plimack
  • Marc S. Ernstoff
  • Lionel D. Lewis
  • Todd M. Bauer
  • David F. McDermott
  • Michael Carducci
  • Christian Kollmannsberger
  • Brian I. Rini
  • Daniel Y. C. Heng
  • Jennifer Knox
  • Martin H. Voss
  • Jennifer Spratlin
  • Elmer Berghorn
  • Lingfeng Yang
  • Hans J. Hammers
Open Access
Correction

Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:109

https://doi.org/10.1186/s40425-018-0420-0

Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable.” should be replaced with “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable.” (3.0% instead of 0.3%).

The publisher apologizes for any inconvenience caused by this error.

Reference

  1. 1.
    Amin A, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109.  https://doi.org/10.1186/s40425-018-0420-0.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Asim Amin
    • 1
    Email author
  • Elizabeth R. Plimack
    • 2
  • Marc S. Ernstoff
    • 3
  • Lionel D. Lewis
    • 4
  • Todd M. Bauer
    • 5
  • David F. McDermott
    • 6
  • Michael Carducci
    • 7
  • Christian Kollmannsberger
    • 8
  • Brian I. Rini
    • 9
  • Daniel Y. C. Heng
    • 10
  • Jennifer Knox
    • 11
  • Martin H. Voss
    • 12
  • Jennifer Spratlin
    • 13
  • Elmer Berghorn
    • 14
  • Lingfeng Yang
    • 14
  • Hans J. Hammers
    • 15
  1. 1.Immunotherapy program, Levine Cancer InstituteCarolinas HealthCare SystemCharlotteUSA
  2. 2.Division of Genitourinary Medical Oncology, Department of Hematology/OncologyFox Chase Cancer CenterPhiladelphiaUSA
  3. 3.Division of Oncology, Department of MedicineRoswell Park Cancer InstituteBuffaloUSA
  4. 4.Department of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical CenterLebanonUSA
  5. 5.Sarah Cannon Research Institute/Tennessee Oncology, PLLCNashvilleUSA
  6. 6.Department of Medicine, Beth Israel Deaconess Medical CenterDana-Farber/Harvard Cancer CenterBostonUSA
  7. 7.Department of OncologyJohns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimoreUSA
  8. 8.Division of Medical OncologyBritish Columbia Cancer AgencyVancouverCanada
  9. 9.Lerner College of Medicine, Department of Hematology and OncologyCleveland Clinic Taussig Cancer InstituteClevelandUSA
  10. 10.Department of Oncology, Tom Baker Cancer CenterUniversity of CalgaryCalgaryCanada
  11. 11.Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer CentreTorontoCanada
  12. 12.Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  13. 13.Department of Oncology, Cross Cancer InstituteUniversity of AlbertaEdmontonCanada
  14. 14.Oncology - Global Clinical ResearchBristol-Myers SquibbPrincetonUSA
  15. 15.Department of Internal MedicineUT Southwestern – Kidney Cancer ProgramDallasUSA

Personalised recommendations